Objective. -Previous studies have shown that a customized biomechanical therapy can improve symptoms of knee osteoarthritis. These studies were small and did not compare the improvements across gender, age, BMI or initial severity of knee osteoarthritis. The purpose of this study was to evaluate the effect of new biomechanical therapy on the pain, function and quality of life of patients with medial compartment knee osteoarthritis. Methods. -Six hundred and fifty-four patients with medial compartment knee osteoarthritis were examined before and after 12 weeks of a personalized biomechanical therapy (AposTherapy). Patients were evaluated using the Western Ontario and McMaster Osteoarthritis (WOMAC) Index and SF-36 Health Survey.
Introduction
Knee osteoarthritis (OA) is associated with symptoms of pain and functional disability. Physical disability arising from pain and loss of functional capacity reduces quality of life and increases the risk of further morbidity. Current treatments aim at alleviating these symptoms, and some of them address biomechanical factors as well.
Several biomechanical interventions for the treatment of knee OA have been presented. The aims of these interventions are to reduce pain and improve function in patients with knee OA. These interventions attempt to unload the diseased articular surface and in some cases also promote controlled perturbation to train neuromuscular control, usually by means of wedge insoles, foot orthoses and valgus braces [4, 13, 18, 20, 21, 27, 29, 35] . One such biomechanical intervention (AposTherapy) has been presented. In recent studies, Elbaz et al. and Bar-ziv et al. [3, 10] found that patients with knee OA who completed an 8-week biomechanical exercise program reported significant improvements in the level of pain and function, as well as improvement in spatiotemporal gait parameters. The effect of this device on knee adduction moment (KAM), which is highly associated with knee OA, and muscle activation pattern, has also been reported in several studies [14, 17] . To date, all published papers regarding this new therapy were carried out on a relatively small sample size. Furthermore, there is yet to be published a randomized clinical trial regarding the effect of this therapy.
Knee OA is twice as common in women as in men, and usually occurs bilaterally [5, 12, 22] . In end stage knee OA, women undergo almost twice as many knee joint replacement surgeries as men [22] . The fact that men and women have similar rates of occurrence of OA at the hip [25, 26] , argues somewhat against a systemic factor such as estrogen, and in favor of local biomechanical factors as the root cause of knee OA. Although certain gender differences in knee joint anatomy and in biomechanical characteristics have been described [1, 6, 19] , there is a lack of information comparing the effect of knee OA treatments in males and females, especially in the case of biomechanical treatments.
Knee OA is also much more prevalent in the elderly, specifically individuals 60 years of age and older [8, 26] . A couple of studies have shown that knee OA prevalence is even greater in patients 85 years of age and older [6, 37] . A study by Elbaz et al. showed that mainly functional symptoms of knee OA worsen with age [9] . Fewer studies, however, have examined if and how biomechanical therapies for knee OA work in different age groups.
The current study was conducted on a large cohort of patients with medial compartment knee OA and was designed to examine the effect of therapy on gender, age and Body Mass Index (BMI) groups, as well as across the initial symptomatic severity of patients.
Patients and methods

Participants
This was a retrospective study. A search for eligible data was performed on the research database of AposTherapy Center. Five thousand six hundred and eighty-two people began AposTherapy between April 2009 and September 2010. Three thousand five hundred and twenty-nine patients did not have primary bilateral knee OA. One thousand one hundred and forty-eight patients did not have questionnaires at either baseline or following 3 months of therapy. Three hundred and fifty-one patients were excluded based on the exclusion criteria. Six hundred and fifty-four patients, 446 females (68.2%) and 208 males (31.8%), diagnosed with symptomatic bilateral medial compartment knee OA participated in this study. Two hundred and eighty-nine (44%) patients reported both legs to be equally symptomatic, 209 (32%) patients reported their right leg to be more symptomatic and 156 (24%) patients reported their left leg to be more symptomatic. Mean age (mean AE SD) was 64.7 AE 8.9 years, mean height was 162.3 AE 9.1 cm and mean weight was 84.4 AE 31.3 kg.
Inclusion criteria included: patients who were examined by their personal physician in the community with bilateral medial compartment knee OA for at least 6 months and who fulfilled the American College of Rheumatology (ACR) clinical criteria for OA of the knee [2] , and were referred to the therapy center. All patients, each of whose charts were reviewed in the present study, were referred to our clinic (AposTherapy center) by their personal physician after being diagnosed with knee OA. This diagnosis was established via a thorough evaluation of the patients by the physician and included a clinical examination and radiographic assessment. When arriving to the therapy center, patients are already diagnosed with radiological knee OA (i.e. radiographs presented signs of OA and no signs of conditions which can mimic OA were present); patients who completed the Western Ontario and McMaster Osteoarthritis Index (WOMAC) questionnaire [32] and Short Form Health Survey (SF-36) [24] at the start of therapy (study baseline) and after 12 weeks of therapy.
Exclusion criteria included:
neurological and rheumatic inflammatory diseases; corticosteroid injection within 3 months of the study; earlier knee surgery excluding arthroscopy; joint replacement of the hip or knee; instability of the knee due to traumatic ligament injury; significant OA in other lower extremity joints.
The protocol was approved by the Institutional Helsinki Committee Registry of Assaf Harofeh Medical Center, Zerifin, Israel (Helsinki registration number 141/08 and NIH clinical trial registration number NCT00767780).
Treatment device
A novel biomechanical device (Apos System, APOSMedical and Sports Technologies Ltd. Herzliya, Israel) comprised of convex adjustable pods placed under the hind-foot and fore-foot regions of each foot was used. This device enables customize calibration of the pods (i.e. biomechanical elements) which allow for control of body alignment and promotion of perturbation throughout all phases of the step-cycle (Fig. 1 ).
Pain, function and quality of life analysis
Changes in pain, function and quality of life perception were evaluated using the WOMAC questionnaire and SF-36 Health Survey. The WOMAC questionnaire is a visual analogue scale (VAS) ranging from 0 to 100 mm, with 0 mm indicating no pain or limitation in function and 100 mm indicating the most severe pain or limitation in function. The SF-36 is scored between 0 and 100, with 0 indicating the worst quality of life and 100 indicating the best quality of life.
Study protocol
Prior to their first and second examinations, patients were instructed not to consume pain medication for at least 72 hours in order to eliminate the effect of these medications on the patient's pain levels. Anthropometric measurements were drawn from the medical file of the patients. All patients completed the WOMAC questionnaire and the SF-36 health survey during their first visit to the therapy center. Patients were guided to complete the WOMAC questionnaire based on the overall condition of their knees. Patients were also guided to complete the SF-36 questionnaire based on their overall health condition. After the completion of the baseline measurements, the biomechanical device was individually calibrated to each patient by a physiotherapist certified in AposTherapy methodology. The principle of calibration is to bring each patient's joint to a position that allows for diminished pain while walking. In medial compartment knee OA, as was the case for all our patients, the element under the hind-foot is shifted laterally from the baseline position. This is done until the patient reports minimal pain during initial contact. The element under the forefoot is shifted medially from the baseline position until the patient reports minimal pain during midstance to toe-off. Biomechanically, by shifting the elements in the coronal plain, the device changes the foot's COP during gait, thus altering the orientation of the ground reaction force (GRF) vector and reducing the knee adduction forces during gait as well. This decreases the pressure load from the affected area (medial compartment) in the joint during gait [15, 16] .
Once the desired alignment is achieved, the patient usually reports immediate pain relief while walking. All patients received exercise instructions and began the therapy the day after the first visit to the therapy center. Treatment was then initiated and continued on a daily basis for a period of 12 weeks. Patients were instructed to put on the biomechanical device and go about their activities of daily living (ADL) for 10 min once a day during the first week, and gradually increase to 30 min once a day at the fourth week and for the rest of the treatment period. Patients returned for a follow-up examination after 3-4 weeks from initial consultation. If necessary, the Apos system was recalibrated. The patient then continued with the therapy in his or her own personal environment according to the physiotherapist's instructions. After 12 weeks of treatment, patients underwent a second WOMAC questionnaire and SF-36 Health Survey.
Statistical analysis
With a sample size of 250, the study will have power of 80% to yield a statistically significant result. This computation assumes that the mean difference is at least 5.0 and the common within-group standard deviation is 20.0. This effect (difference of 5 points in each scale) was selected as the smallest effect that would be important to detect, in the sense that any smaller effect would not be of clinical or substantive significance. Mean and standard deviation for all the continuous variables and the mean differences with 95% confidence intervals (CI) were presented for all the continuous variables. The distributions of the questionnaire scales were examined using the KolmogorovSmirnov non-parametric test. Paired t-tests were calculated to assess the differences between the repeated measures of the questionnaire scales during follow-up. Tests were also conducted for sub-group analysis. The relationships between the baseline measurements and the improvements level during follow-up were assessed by the Spearman correlation. Data were analyzed with SPSS software version 19.0. The significance levels were set at 0.05.
Results
Baseline levels of pain, function, stiffness and quality of life are presented in Table 1 . There were no reports of any adverse events including imbalance, tripping or other physical problems during the study period. All patients complied completely with the treatment protocol. Compliance was verified via a telephone call at several points during the study.
After 12 weeks of treatment, the WOMAC-pain and WOMAC-function subscales were significantly lower compared to baseline (Table 1) . Pain decreased by 30% (P 0.001) and function improved by 29% (P 0.001). All eight categories of the SF-36 health survey significantly improved after 12 weeks of treatment (Table 1) .
To find the specific effect of the treatment in sub-groups, a further analysis on the WOMAC and SF-36 overall score was carried out. Significant differences between genders were found at baseline in the WOMAC-pain, WOMAC-stiffness and WOMAC-function categories. Females reported higher levels of pain (11.6%), stiffness (15.3%) and functional limitation (7.1%). No significant gender differences were seen in the eight categories of the SF-36 at baseline. Both males and females showed significant improvement in all WOMAC and SF-36 subcategories following 12 weeks of therapy. Results are summarized in Table 2 .
Age was divided based on the median age (66 years). There were significant differences in the baseline values between the two age groups in WOMAC-pain and WOMAC-stiffness. The younger group (< 66 years) reported higher levels of pain (10%) and functional limitation (15.8%) compared to the older group (> 66 years). The WOMAC-function and all SF-36 categories were not significantly different between the two groups at baseline. Both age groups showed significant improvement in all WOMAC and SF-36 categories following 12 weeks of therapy. Results are summarized in Table 3 .
Another examination was carried out according to the patients' BMI. Two groups of patients were defined: patients with a BMI less or equal to 28.0 kg/m 2 and patients with a BMI greater than 28.0 kg/m 2 . There were significant differences in the baseline values between the two groups in WOMAC-pain, WOMAC-stiffness and WOMAC-function. The lighter weight group (BMI 28.0 kg/m 2 ) reported lower levels of pain (9.3%), stiffness (12.4%) and functional limitation (15.0%) compared to the heavier weight group (BMI > 28.0 kg/m 2 ). All SF-36 categories were not significantly different between the two groups at baseline. After 3 months of therapy there were significant differences between groups in WOMAC-function. Both BMI groups showed significant improvement in all WOMAC and SF-36 categories following 12 weeks of therapy, except for the SF-36 energy subscale in which the lighter BMI group did not improve significantly. Results are summarized in Table 4 . . The WOMAC questionnaire includes 24 questions in a Visual Analogue Scale (VAS) format (0 = no pain/stiffness/difficulty, 100 = severe pain/stiffness/difficulty). The criteria for clinical response to a treatment had been defined by the Outcome Measures in Rheumatology Clinical Trials (OMERACT) and Osteoarthritis Research Society International (OARSI). They are either an improvement in pain or in function of at least 50% with a decrease of 2.0 cm on the VAS for pain or function, or an improvement in both pain and function of at least 20% with a decrease of 1.0 cm on the VAS. The average improvements in the WOMAC pain and function scales meet the OMERACT-OARSI criteria. Furthermore, individually, 56% of the patients met the OMERACT-OARSI criteria (improved) whereas 18% of the patients improved but did not meet these criteria.
b SF-36 Health Survey includes 36 questions. Results range between 0-100 (0 = poor quality of life, 100 = high quality of life).
In order to determine the relationship between the magnitude of the effect of therapy and the severity of symptoms before therapy, a correlation between the baseline values and the level of improvement (the difference between the tests at the endpoint and baseline) was calculated. A significant moderate positive correlation was found for all WOMAC and SF-36 domains (Fig. 2) . A moderate correlation means that at least part of the observed improvement in a specific scale is a result of its level at baseline. Furthermore, the success rate of the therapy in all WOMAC and SF-36 subcategories was Results presented as mean (SD). y P-value was set to P < 0.05. Represents the differences between genders at baseline; yy P-value was set to P < 0.05. Represents the differences between genders at the 3 months time point; yyy P-value was set to P < 0.05. Represents the differences between baseline and 3 months in females; yyyy P-value was set to P < 0.05. Represents the differences between baseline and 3 months in males. a Western Ontario and McMaster Universities Index (WOMAC Index). The WOMAC questionnaire includes 24 questions in a VAS format (0 = no pain/stiffness/ difficulty, 100 = severe pain/stiffness/difficulty).
b SF-36 Health Survey includes 36 questions. Results range between 0-100 (0 = poor quality of life, 100 = high quality of life). Results presented as mean (SD). y P-value was set to P < 0.05. Represents the differences between the two age groups at baseline; yy P-value was set to P < 0.05. Represents the differences between the two age groups at the 3 months time point; yyy P-value was set to P < 0.05. Represents the differences between baseline and 3 months in patient under the age of 65; yyyy P-value was set to P < 0.05. Represents the differences between baseline and 3 months in above the age of 66. a Western Ontario and McMaster Universities Index (WOMAC Index). The WOMAC questionnaire includes 24 questions in a VAS format (0 = no pain/stiffness/ difficulty, 100 = severe pain/stiffness/difficulty).
calculated. The therapy was considered successful if the patient reported a reduction in pain, an improvement in function and an improvement in quality of life. The percent of patients reporting an improvement in symptoms was calculated. Overall, the success rate of this therapy was approximately 75% based on the patient's pain, function and quality of life report.
Discussion
The current study examined the effect of a 3-month biomechanical therapy program in a cohort of patients with medial compartment knee OA. The aim of the study was to evaluate changes in pain, function and quality of life using the WOMAC and SF-36 questionnaires.
The results of this study suggest that there was a significant improvement in pain and function. After 12 weeks of therapy with the biomechanical device, the WOMAC and SF-36 results showed that patients reported significant improvements in the level of pain, function and quality of life. This was consistent in younger patients, older patients, males and females. The improvements also met the OMERAC-OARSI guidelines for the minimum improvement threshold that would have a true Results presented as mean (SD). y P-value was set to P < 0.05. Represents the differences between the two BMI groups at baseline; yy P-value was set to P < 0.05. Represents the differences between the BMI age groups at the 3 months time point; yyy P-value was set to P < 0.05. Represents the differences between baseline and 3 months in patient with BMI 28.0; yyyy P-value was set to P < 0.05. Represents the differences between baseline and 3 months in patients with BMI > 28.0. a Western Ontario and McMaster Universities Index (WOMAC Index). The WOMAC questionnaire includes 24 questions in a VAS format (0 = no pain/stiffness/ difficulty, 100 = severe pain/stiffness/difficulty).
b SF-36 Health Survey includes 36 questions. Results range between 0-100 (0 = poor quality of life, 100 = high quality of life). positive impact on the patient [28] . The results of the present study are support by previous works. Bar-Ziv et al. examined the effect of this therapy in a double-blind study conducted on fifty-seven patients with bilateral knee OA [3] . They reported a significant improvement in function and reduction in pain following 8 weeks of therapy in the experimental group and no changes in the level of pain and function of the control group. The current study supports their findings with a larger number of patients and over a longer study period. KAM reflects the compressive forces acting on the medial aspect of the knee and is widely considered as a maker for the severity of knee OA [34] . Previous studies have found a correlation between KAM and the levels of pain in knee OA population [22, 23, 31] . Reeves et al. conducted an extensive review on the effect of conservative biomechanical intervention strategies aimed at reducing KAM and found several noninvasive biomechanical interventions that reduce KAM, including lateral wedge insoles (4-14% reduction in KAM), variable-stiffness shoes (6% reduction in KAM), cane or walking sticks (10% reduction in KAM) and valgus knee braces (8-17% reduction in KAM) [30] . Haim et al. found that 9 months of AposTherapy led to a reduction of 18% in KAM while walking barefoot [17] . It may be postulated that the reduction in KAM was accompanied with a reduction in pain, and since KAM and pain are associated, a higher reduction in KAM will be accompanied with a higher reduction in pain.
The present study also examined knee OA gender differences in pain, function and quality of life both before and after 12 weeks of therapy. At baseline, females showed significantly worse symptoms in all WOMAC categories at baseline, while no significant gender differences were found in the SF-36 categories. After 12 weeks of AposTherapy, no significant differences were found in any of the categories. Previous studies have also examined gender difference in knee OA. Debi et al. also reported gender differences in the perception of pain and function in patients with knee OA [6] . Specifically they showed that females report higher levels of pain and functional disability than males. Additionally, Tsai et al. reported gender differences in pain sensation and functional performance showing that females reported higher levels of pain intensity compared to males [36] . These studies support the findings of baseline gender differences in the present study. In combination with the results of previous studies, these findings suggest that females may experience worse symptoms of knee OA compared to males. After therapy both genders showed improvements in all categories; however, the gender differences observed at baseline were no longer discernable. This suggests that females may improve with therapy to a greater extent than male patients. Future studies should further examine knee OA gender differences regarding responsiveness to therapy in general, and to this biomechanical therapy specifically. That is to say, future studies should examine if males and females improve in the same amount in other biomechanical measurements such as gait patterns, muscle force, muscle activation, etc.
The present study also examined the differences between younger and older knee OA patients (divided at the median age of 66 years) in pain, function and quality of life both before and after 12 weeks of therapy. As opposed to gender, the association between age and the severity of knee OA symptoms was not well determined. At baseline younger patients showed significantly worse symptoms in WOMAC pain and stiffness categories but not in the WOMAC function category or any of the SF-36 categories. This finding was in contradiction with previous studies. Elbaz et al. observed that an increase in age was associated with a significant deterioration of function on the WOMAC function category and SF-36 physical functioning category [9] . They found no such association in the WOMAC pain, WOMAC stiffness or any other SF-36 category. This contradicts the present study which showed younger patients to have worse symptoms, and that those symptoms are mainly found in the pain categories. A possible explanation for the pain difference between young (under 66) and old (above 66) patients with knee OA may be the fact the younger population is more active than the older population. According to Sharma et al., one of the factors that place patients with knee OA at greater risk of a poor function is age [33] . Since being more active means bearing more loads on the knees, it may be assumed that higher pain levels may occur. After 12 weeks of biomechanical therapy, the present study showed that the age difference in knee OA severity were no longer discernable in any of the WOMAC or SF-36 categories. This suggests that younger patients may improve with therapy to a greater extent than older patients. Future studies should evaluate the age difference in knee OA severity in greater depth. In regard to BMI, it seems that patients with a BMI greater than 28 kg/m 2 benefitted slightly more compared to the lighter BMI group. Although both groups improved significantly, the heavier group improved to a greater extent.
When evaluating the effect of a new therapy for knee OA it is important to understand its effect on patients suffering from different levels of severity of the disease. For this reason, a correlation was calculated between the baseline levels of pain and function and the magnitude of improvement in pain and function with therapy. Moderate correlations were found between the magnitude of improvement with therapy and the symptomatic severity of the patients at baseline, meaning that the initial level of symptoms only partially affected the magnitude of the outcomes. Initially it was expected that the greater the level of symptoms the more of an effect the therapy would have. One explanation for this may be that questionnaires are subjective and depend on the patient's perceptions. The results may be influenced by numerous behavioral, psychological, emotional factors and others and may not reflect the true effect of therapy. Ideally, the subjective results should be accompanied with a validated objective measure that can evaluate the functional severity. A recent study has suggested gait parameters to help objectively quantify functional severity of patients with knee OA [11] . Another explanation may be that there was less of a reduction in pain because of the increase in function.
Overall, it seems as though patients with worse symptoms may improve more with therapy than patients with moderate or low levels of symptoms. These findings shed further light on the results of the age and gender analyses. Those analyses suggested that younger patients and female patients improved to a greater extent than older patients and male patients. The younger patients and female patients, however, were those with worse symptoms. In light of this, the present correlation findings give a possible explanation: younger patients and females patients improved to a greater extent because they began with worse symptoms and not necessarily because they were younger or were females. It may be postulated that patients with severe symptoms of pain and functional limitation will experience higher improvement compared to patients with less severe symptoms. However, a more extensive evaluation of this assumption is needed in a prospective study that will examine the efficacy of the treatment at different pain and functional levels followed by an objective evaluation such as a gait analysis.
The success rate of this therapy was measured based on the changes in the self-reported questionnaires and showed an overall 80% of improvement in pain and function after 3 months of AposTherapy. This value, however, cannot be fully determined by this study and should be further examined in future studies.
This study had some limitations. First, the study lacked a control group. A previous study, however, by Bar-Ziv et al. [3] already showed the positive effect of this therapy compared to a control group in a double blind study. Second, the study had a short follow-up duration and as such can only stand as evidence to the short-term effects of this therapy. The results of this study support the findings of previous examinations of this therapy [3, 10, 14, 17] so it may be assumed that this therapy has a true impact on the patients rather than a placebo effect or simply part of the natural evolution of the disease. Nevertheless, future studies should examine the long-term effects of this therapy. Third, this study did not include radiographic assessment of the patients' knees. Radiographic evaluation of structural changes in the knee joint is an integral process in knee OA assessment. The correlation, however, between structural severity and knee OA symptoms is poor [7] . The purpose of this study was to examine the clinical effect of this therapy in patients with knee OA and therefore we did not find it relevant to incorporate radiographic evaluation. Future studies should examine the effect of this therapy on structural changes at the knee joint. Fourth, the study only examined the effects of AposTherapy on patients with medial compartment knee OA. Further work is necessary to elucidate how this therapy affects patients with other types of knee OA.
In conclusion, patients with medial compartment knee OA treated by AposTherapy for 12 weeks showed statistically and clinically significant improvements in pain, function and quality of life. In light of this evidence, AposTherapy may be a useful tool for treating patients with medial compartment knee OA. 
Version française
Introduction
La gonarthrose est associée à des symptômes douloureux et une incapacité fonctionnelle. Cette incapacité liée à la douleur et la perte fonctionnelle réduit la qualité de vie et augmente le risque de co-morbidités. Les traitements actuels visent à soulager les symptômes, et certains s'intéressent plus spécialement aux facteurs biomécaniques.
Plusieurs solutions biomécaniques dans l'approche thérapeu-tique de la gonarthroses ont été proposées. Le [3, 10] , des patients avec une gonarthrose ayant suivi un programme d'exercices biomécaniques sur une période de huit semaines rapportaient une amélioration significative de leur douleur et capacité fonctionnelle, ainsi qu'un effet positif sur les paramètres spatiotemporels de la marche. Les effets de ce système sur le moment d'adduction du genou, qui comme nous le savons est fortement associé à la gonarthrose, et sur le schéma d'activation musculaire ont été rapportés dans plusieurs études [14, 17] . À ce jour, toutes les études publiées sur cette nouvelle thérapeutique concernaient des petits échantillons de patients. De plus, aucune étude clinique randomisée n'a encore été publiée sur l'impact de cette thérapie. La gonarthrose est deux fois plus fréquente chez les femmes que chez les hommes et concerne habituellement les deux genoux [5, 12, 22] . Dans la phase finale de la gonarthrose, les femmes sont deux fois plus nombreuses à recourir à la chirurgie que les hommes [22] . Le fait que les hommes et les femmes aient le même taux de survenue de coxarthrose [25, 26] écarte un facteur de causalité systémique comme les estrogènes en faveur de facteurs biomécaniques locaux à la source de la gonarthrose. Bien que certaines différences entre hommes et femmes dans l'anatomie articulaire du genou et les caractéristiques biomécaniques ont été rapportées [1, 6, 19] , il y a peu de données disponibles comparant les effets des traitements de la gonarthrose chez l'homme et chez la femme, tout spécialement dans le cas de thérapeutiques biomécaniques.
La prévalence de la gonarthrose est plus élevée chez la personne âgée, tout spécialement chez les adultes de plus de 60 ans [8, 26] . Quelques études montrent que la prévalence de la gonarthrose est encore plus importante chez les adultes de plus de 85 ans [6, 37] . Une étude par Elbaz et al. montre que ce sont particulièrement les symptômes fonctionnels de la gonarthrose qui s'aggravent avec l'âge [9] 
Matériel thérapeutique
Cet équipement novateur biomécanique (Apos System, APOS-Medical and Sports Technologies Ltd, Herzliya, Israël) est composé d'éléments biomécaniques convexes ajustables placés sous le talon et la plante de chaque pied. Ce système permet d'ajuster la calibration de ces éléments biomécaniques afin de contrôler l'alignement du corps et promouvoir les perturbations durant toutes les phases du passage du pas (Fig. 1 ).
É valuation de la douleur, de la capacité fonctionnelle et de la qualité de vie
Les changements au niveau de la douleur, capacité fonctionnelle et perception de la qualité de vie ont été évalués à l'aide du questionnaire WOMAC et du questionnaire généraliste SF-36 sur la qualité de vie. Le questionnaire WOMAC est une échelle visuelle analogique (EVA) allant de 0 à 100 mm, 0 correspondant à l'absence de douleur ou de limitation fonctionnelle et 100 mm indiquant une douleur extrême ou limitation fonctionnelle maximale. Le questionnaire SF-36 va de 0 à 100, 0 correspond à la qualité de vie la plus mauvaise et 100 à la qualité de vie la meilleure.
Protocole de l'étude
Avant chacun des deux examens cliniques, il était recommandé aux patients de ne prendre aucun antalgique dans les 72 heures précédant l'évaluation afin d'éliminer les effets de ces médicaments sur l'intensité de la douleur. Les données anthropométriques étaient issues des dossiers médicaux des patients. Tous les patients ont complété les questionnaires WOMAC et SF-36 qualité de vie pendant leur première visite au centre. Les patients étaient guidés pour compléter le questionnaire WOMAC en fonction de la condition générale de leurs genoux et le SF-36 en fonction de l'appréciation globale de leur état de santé. Après prise des mesures nécessaires à la visite d'inclusion, l'appareil biomécanique était calibré individuellement en fonction de chaque patient par un kinésithérapeute formé à la méthodologie de la thérapie Apos. Le principe de cette calibration était de positionner l'articulation de chaque patient de telle sorte que la douleur soit diminuée pendant la marche. Dans le cas d'une gonarthrose du compartiment fémorotibial interne, pathologie commune à tous nos patients, l'élément convexe sous le talon était poussé latéralement à partir de la position initiale jusqu'à ce que le patient ressente le moins de douleur possible au contact initial du talon avec le sol. L'élément situé sous l'avant du pied était glissé horizontalement jusqu'à ce que le patient rapporte le moins de douleur possible à la pose de l'avant du pied sur le sol. Au niveau biomécanique, lorsqu'on glisse ces éléments sur le plan coronal, le système change le centre de pression du pied au cours de la marche, altérant ainsi le vecteur des forces de réaction au sol et réduisant également le moment d'adduction du genou pendant la marche.
Cela diminue la pression d'appui de la partie atteinte (compartiment fémorotibial interne) sur l'articulation pendant la marche [15, 16] .
Une fois l'alignement désiré obtenu, le patient rapportait normalement une diminution immédiate de la douleur pendant la marche. Tous les patients ont reçu des instructions sur la façon de faire les exercices avant de commencer la thérapie le jour après leur première visite au centre. Le traitement a été poursuivi pendant une période de 12 semaines. Les patients devaient mettre le système biomécanique et ensuite vaquer à leurs activités quotidiennes pendant dix minutes chaque jour au cours de la première semaine, et augmenter graduellement le temps de port du système jusqu'à 30 minutes chaque jour à la quatrième semaine et pour le reste du traitement. Les patients revenaient pour un examen de suivi trois à quatre semaines après la première visite. Si nécessaire, le système Apos était recalibré. Le patient continuait ensuite la thérapie dans son propre environnement suivant les instructions du kinésithérapeute. Après 12 semaines de traitement, les patients remplissaient une seconde fois les questionnaires WOMAC et SF-36.
Analyse statistique
Avec sa cohorte de 250 patients, l'étude atteint un pouvoir statistique de 80 % permettant de produire des résultats statistiquement significatifs. Ces calculs se basent sur une différence moyenne d'au moins 5,0 et une déviation standard du groupe témoin de 20,0. Cette différence de cinq points dans chacune des échelles est considérée comme la différence minimale à détecter pour avoir de l'importance, c'est-à-dire que toute différence inférieure à 5,0 ne serait pas significative sur un plan clinique.
Les moyennes et écarts-types pour toutes les variables ainsi que les différences moyennes avec un intervalle de confiance de 95 % (confidence interval = CI) étaient notés pour toutes les variables continues. Les distributions des échelles des questionnaires étaient évaluées à l'aide du test non-paramé-trique de Kolmogorov-Smirnov. Les t-tests appariés ont été utilisés pour calculer les différences entres les mesures répétées des questionnaires au cours des examens de suivi. Des tests ont été également menés pour analyser les sous-groupes. Les relations entre les mesures initiales et les niveaux d'améliora-tion rapportés lors du suivi ont été évaluées par le test de corrélation de Spearman. Les données ont été analysées avec le logiciel SPSS version 19.0. Les niveaux de différence significatifs étaient estimés à 0,05.
Résultats
Les mesures de la douleur, capacité fonctionnelle, raideur et qualité de vie sont présentées dans le Tableau 1. Aucun effet secondaire n'a été rapporté, pas de perte d'équilibre, chute ou autres problèmes physiques durant la durée de l'étude. Les patients ont adhéré totalement au protocole de l'étude. L'observance était vérifiée par téléphone plusieurs fois au cours de l'étude. Après 12 semaines de traitement on notait une diminution significative des sous-échelles WOMAC-douleur et WOMAC-capacité fonctionnelle en comparant les données post-traitement aux données obtenues lors de la visite initiale (Tableau 1). Les huit catégories du questionnaire généraliste SF-36 montraient une amélioration significative après 12 semaines de traitement (Tableau 1). Afin de mesurer l'impact spécifique du traitement dans chaque sous-groupe, une analyse complémentaire a été effectuée sur les scores globaux du WOMAC et du SF-36. Des différences significatives entre les sexes ont été notées durant la visite initiale dans les catégories WOMAC : douleur, raideur et fonction. Les femmes rapportaient un niveau plus élevé sur les items douleur (11,6 %), raideur (15,3 %) et limitation fonctionnelle (7,1 %). Aucune différence significative n'a été trouvée pour les huit catégories du SF-36 à la visite d'inclusion. Les hommes et les femmes montraient des améliorations significatives dans les sous-catégories du WOMAC et du SF-36 après 12 semaines de traitement. Les résultats sont listés dans le Tableau 2. Les groupes d'âge ont été définis suivant l'âge moyen (66 ans). Des différentes significatives ont été rapportées dans les valeurs obtenues à la visite initiale entre les deux groupes d'âge pour les catégories WOMAC-douleur et WOMAC-raideur. Le groupe le plus jeune (< 66 ans) a rapporté des niveaux plus élevés pour la douleur (10 %) et la limitation fonctionnelle (15,8 %) comparée au groupe plus âgé (> 66 ans). Aucune différence significative n'a été rapportée entres les deux groupes à la visite Fig. 2) . Une corrélation modérée montre qu'au moins une partie de l'amélioration observée dans une échelle spécifique est le résultat de son niveau à la visite d'inclusion. De plus, le taux de succès de la thérapie a été calculé pour toutes les sous-catégories du WOMAC et SF-36. Le traitement était réussi si le patient rapportait une diminution de la douleur, une amélioration de la capacité fonctionnelle et de la qualité de vie. Nous avons également évalué le pourcentage des patients rapportant une amélioration des symptômes. Globalement le taux de succès de cette thérapeu-tique biomécanique était de 75 %, avec des patients rapportant une amélioration significative de leur douleur, capacité fonctionnelle et qualité de vie. b SF-36 questionnaire généraliste qui comprend 36 questions. Les résultats varient de 0 à 100 (0 = mauvaise qualité de vie, 100 = excellente qualité de vie). invasives réduisant le moment d'adduction du genou, notam [11] . Une autre explication possible pourrait être que la douleur était moins diminuée parce que justement la capacité fonctionnelle était nettement améliorée. Globalement, il semble que les patients ayant des symptômes sévères s'améliorent plus avec traitement que les patients ayant des symptômes modérés à faibles. Ces résultats contribuent à éclaircir les résultats des analyses suivant la différence d'âge et de sexe. Ces analyses suggèrent que les patients plus jeunes et les femmes rapportent une amélioration plus importante que les patients plus âgés et les hommes. Cependant les patients les plus jeunes et les femmes étaient ceux ayant les symptômes les plus sévères, donc la corrélation trouvée dans les résultats donne une explication possible : les patients jeunes et les femmes rapportent une amélioration plus grande parce que leurs symptômes étaient plus sévères au début et pas nécessairement parce qu'ils sont plus jeunes ou que ce sont des femmes. On peut envisager que les patients rapportant une douleur et une limitation fonctionnelle plus sévère s'amélior-eront plus que les patients avec des symptômes plus modérés. Cependant, une évaluation plus précise de cette hypothèse devra faire l'objet d'une future étude prospective pour examiner l'efficacité du traitement sur différents niveaux de douleur et de limitation fonctionnelle et l'associer à une évaluation objective telle qu'une analyse de la marche. Le taux de succès de ce traitement a été mesuré en fonction des changements auto-rapportés dans les questionnaires et montre une amélioration globale de 80 % pour la douleur et la capacité fonctionnelle après trois mois d'AposTherapy. Cependant, cette valeur ne peut pas être complètement validée par cette étude et doit faire l'objet d'autres travaux futurs. Cette étude montre également certaines limites. Premièrement, l'absence de groupe témoin. Cependant, une étude précédente en double insu par Bar-Ziv et al. [3] montrait déjà l'effet positif de ce traitement comparé avec un groupe témoin. Deuxième-ment, notre étude avait un suivi trop court et donc ne peut souligner que les effets à court terme de ce traitement. Les résultats de cette étude rejoignent ceux des précédentes études sur cette thérapie [3, 10, 14, 17] , nous pouvons donc conclure que ce traitement a un impact réel sur les patients et n'est pas dû à un effet placebo ou une évolution naturelle de la maladie. Troisièmement, cette étude n'incluait pas les comptes rendus d'imagerie des genoux de nos patients. Un examen radiographique des changements structurels dans l'articulation du genou fait partie du processus d'évaluation de la gonarthrose. Toutefois, la corrélation entre la sévérité de l'atteinte structurelle et les symptômes de la gonarthrose reste très faible [7] . Le but de cette étude était d'examiner les effets cliniques de ce traitement sur les patients souffrant de gonarthrose et nous n'avons donc pas vu l'intérêt d'inclure des évaluations radiographiques. Dans le futur, des études devraient rechercher les effets de cette thérapeutique sur les changements structurels au niveau de l'articulation du genou. Quatrièmement, nous avons seulement étudié les effets de l'AposTherapy sur les patients ayant une gonarthrose du compartiment fémorotibial interne. Des travaux complémen-taires sont nécessaires pour vérifier les effets de ce traitement sur d'autres types de gonarthrose. 
Discussion
